Currently out of the existing stock ratings of Martin Auster, 106 are a BUY (66.67%), 44 are a HOLD (27.67%), 9 are a SELL (5.66%).

Martin Auster

Work Performance Price Targets & Ratings Chart

Analyst Martin Auster, carries an average stock price target met ratio of 65.55% that have a potential upside of 25.19% achieved within 211 days. Previously, Martin Auster worked at CREDIT SUISSE.

Martin Auster’s has documented 307 price targets and ratings displayed on 31 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals at 30-Oct-2025.

Wall Street Analyst Martin Auster

Analyst best performing recommendations are on ALXO (ALX ONCOLOGY HOLDINGS ).
The best stock recommendation documented was for ALXO (ALX ONCOLOGY HOLDINGS ) at 11/9/2020. The price target of $62 was fulfilled within 8 days with a profit of $15.41 (33.08%) receiving and performance score of 41.34.

Average potential price target upside

ALXN Alexion Pharmaceuticals ALXO Alx Oncology Holdings  ANAB AnaptysBio ARNA Arena Pharmaceuticals BMRN Biomarin Pharmaceutical ESPR Esperion Therapeutics ETTX Entasis Therapeutics Holdings FLXN Flexion Therapeutics INSM Insmed MYOK MyoKardia PTCT PTC Therapeutics RARE Ultragenyx SLDB Solid Biosciences LLC SPRB Spruce Biosciences  SRPT Sarepta Therapeutics STOK Stoke Therapeutics UTHR United Therapeutics XLRN Acceleron Pharma OBSV ObsEva SA ONCE Spark Therapeutics GLTO Galecto  RXDX Prometheus Biosciences INBX Inhibrx  CVAC CureVac NV KURA Kura Oncology NTLA Intellia Therapeutics ALNA Allena Pharmaceuticals IRWD Ironwood Pharmaceuticals DYN Dyne Therapeutics  ALNY Alnylam Pharmaceuticals BBIO BridgeBio Pharma

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 05-Jan-2015

$205

$22.5 (12.33%)

$150

4 years 9 months 2 days ago
(05-May-2021)

3/5 (60%)

$35.09 (20.65%)

938

Hold Since 23-Mar-2021

$173

$-9.5 (-5.21%)

$156

4 years 9 months 4 days ago
(03-May-2021)

14/24 (58.33%)

$2.73 (1.60%)

682

Buy Since 06-Sep-2019

$175

$-7.5 (-4.11%)

$165

5 years 3 days ago
(04-Feb-2021)

3/3 (100%)

$19.41 (12.48%)

397

Hold Since 14-Dec-2020

$190

$7.5 (4.11%)

$194

5 years 3 days ago
(04-Feb-2021)

9/11 (81.82%)

$34.41 (22.12%)

350

Hold Since 04-Feb-2021

$166

$-16.5 (-9.04%)

$175

5 years 3 days ago
(04-Feb-2021)

23/23 (100%)

$10.41 (6.69%)

828

Show more analysts

Please expand the browser size to see the chart

Which stock is Martin Auster is most bullish on?

Potential upside of $143.84 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Martin Auster is most reserved on?

Potential downside of $0.95 has been obtained for BBIO (BRIDGEBIO PHARMA)

What Year was the first public recommendation made by Martin Auster?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?